AVROBIO, Inc. has entered into an Asset Purchase Agreement with Novartis Pharma AG and Novartis Pharmaceuticals Corporation for the sale of its cystinosis gene therapy program and related assets, with a cash payment of $87.5 million upon closing of the transaction.